An observational study in Polycystic Ovary Syndrome (PCOS), sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-10.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Polycystic Ovary Syndrome with a site in France — 9 open to participants now, 10 under way, 1 of them phase 3. Polycystic Ovary Syndrome · France.
Among the 21 studies in Polycystic Ovary Syndrome with a site in France, this one is one of 5 that started in 2026, is one of 8 observational ones, and was the 19th registered.
959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.
Browse Polycystic Ovary Syndrome studies →9 of the 21 studies in Polycystic Ovary Syndrome with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–45 · Women only
Hospital St. Joseph, Marseille, France · Sites in France
Ages 18–37 · Women only
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+ · Women only
University Hospital, Strasbourg, France · Sites in France
Ages 18–49
CHU de Reims · Sites in France
Ages 18–45 · Women only
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 473 is above the median of 118 across 223 observational studies indexed under Polycystic Ovary Syndrome.
Median enrollment 52 across the 13 interventional studies, 100 across the 8 observational. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 21 have an industry lead sponsor. The 10 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Assistance Publique - Hôpitaux de Paris has 3 studies filed under Polycystic Ovary Syndrome — fewer than ten, so there is no comparison to draw.
4 of the studies in Polycystic Ovary Syndrome with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03059173Phase 3University Hospital, LilleInterest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome | 2027-09-12 |
| NCT07016035CHU de ReimsTranslation and Validation of the French mPCOSQ (mPCOSQ-F). | 2027-05-12 |
| NCT07499518Assistance Publique - Hôpitaux de ParisFertility and Polycystic Ovary Syndrome | 2027-06-01 |
| NCT07483723Centre Hospitalier Universitaire, AmiensGlucose Profiles in Women With Polycystic Ovary Syndrome | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 21 studies in Polycystic Ovary Syndrome with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women of reproductive age and affects approximately 10% of women worldwide. The diagnosis is based on the Rotterdam criteria established in 2003 and updated in the latest recommendations from the European Society of Human Reproduction (ESHRE) in 2023. The diagnosis of PCOS is based on the presence of 2 of the following 3 criteria:
It is therefore a major cause of anovulatory infertility, but its pathophysiological mechanisms remain complex and multifactorial, involving interactions between genetic, metabolic, hormonal, and environmental factors. Prior to embarking on a fertility treatment plan, it is essential to better understand how these various factors influence ovarian function and reproductive capacity in patients with PCOS. Identifying and characterizing factors associated with fertility-such as hormonal profiles, insulin sensitivity, and metabolic markers-could help better predict future fertility and optimize personalized care and fertility outcomes. The aim of this study is therefore to identify modifiable factors influencing the fertility of PCOS patients phenotyped at La Pitié-Salpêtrière hospital.
PCOS patients and healthy PCOS-free participants previously enrolled in METABOPK research at Pitié-Salpêtrière hospital
Inclusion Criteria- PCOS group:
Inclusion Criteria- Control group
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PCOS patients aged between 18 and 45 years
Other: Questionnaires
Control (PCOS free)
Other: Questionnaires
Questionnaires about fertility and potential pregnancies
Description of the mode of conception
Description of the mode of conception: spontaneous or induced; if induced, by which ART technique or following which treatment to improve PCOS symptoms (inositol, GLP-1 analog, metformin, lifestyle and dietary changes, etc.). These informations will be colected from medical records and frome the specific questionnaire.
Time frame: Through study completion, an average of 1 year
Description of the treatment protocols for infertility
Description of the treatment protocols for infertility among women in the cohort, if applicable: The description of infertility will be based on patient reports and treatment records
Time frame: Through study completion, an average of 1 year
Description of obstetric complications
Description of obstetric complications: ectopic pregnancy, miscarriage, intrauterine fetal death, intrauterine growth restriction (IUGR), gestational diabetes, hypertension, preeclampsia, HELLP syndrome, intrahepatic cholestasis of pregnancy, gestational age at delivery, spontaneous or induced labor, birth weight, breastfeeding possible if desired: The description of obstetric complications will be based on data from the specific questionnaire and from pregnancy and delivery follow-up reports.
Time frame: Through study completion, an average of 1 year
Identification of hormonal and metabolic factors associated with infertility and obstetric complications
Identify hormonal and metabolic factors associated with infertility and obstetric complications early on so that appropriate measures can be taken in preparation for starting a family
Time frame: Through study completion, an average of 1 year
Plan to share: Yes — The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor
Access criteria: Researchers who provide a methodologically sound proposal
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Jun 2027, 12 months later.
Of 71 non-industry observational studies under Polycystic Ovary Syndrome, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 47. This study's planned 12 months is below that.
Counting every sponsor, half of 74 studies reached it within 14 months; a quarter within 6 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →